Please sign in to follow a disease.
Which nasal spray works best for hay fever? new study compares two options
NCT ID NCT07415278
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two nasal sprays for moderate-to-severe allergic rhinitis (hay fever): fluticasone alone versus a combination of fluticasone and azelastine. Researchers will track symptom relief and quality of life in 61 adults over two months to see which spray works better and faster.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- fluticasone propionate and azelastine hydrochloride nasal sprays
- What this could lead to
- If the combination spray works better, it could offer a more effective first-line option for people with moderate-to-severe allergic rhinitis.
- What could go wrong
- This is a small, phase 4 study with only 61 participants, so results may not apply to everyone. The difference between the two sprays might be small or not meaningful.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
61 people
The number who actually took part.
- Started
-
Dec 2022
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18 years and older * Clinical symptoms consistent with allergic rhinitis * Positive skin prick test results * Moderate-to-severe allergic rhinitis defined as a Score for Allergic Rhinitis (SFAR) of 7 or higher * Willingness to participate and provide informed consent Exclusion Criteria: * Patients under 18 years of age * Patients with atopic diseases (e.g., atopic dermatitis) or asthma, other than allergic rhinitis * Those with a recent respiratory tract infection, nasal polyps, or septal deviation * Patients who had previously undergone sinonasal surgical treatment * Individuals who use tobacco, alcohol, or illicit drugs * Those who have used the following medications: Antihistamines (within the last week) Nasal or oral decongestants (within the last week) Topical corticosteroids (within the last 2 weeks) Membrane stabilizers (within the last 2 weeks) Leukotriene antagonists (within the last 2 weeks) Systemic corticosteroids (past 4 weeks) Immunotherapy (within the past 5 years) • Patients with allergic rhinitis symptom score \<7
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Allergic rhinitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pamukkale University
Denizli, Pamukkale, 20070, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a needle in the face tame allergy symptoms?
- Can AI make acupuncture more precise for allergy relief?
- Ancient herbal blend put to the test against hay fever
- Can a pinpoint pollen dose unmask allergy triggers?
- Can an antihistamine–steroid combo pill beat standard allergy meds?
- Allergy tablets under the tongue may cut hay fever drug use for years, massive real-world study suggests